Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Standard BioTools Inc (NASDAQ: LAB) was $1.3 for the day, up 1.56% from the previous closing price of $1.28. In other words, the price has increased by $1.56 from its previous closing price. On the day, 1.63 million shares were traded. LAB stock price reached its highest trading level at $1.32 during the session, while it also had its lowest trading level at $1.27.
Ratios:
Our analysis of LAB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.37 and its Current Ratio is at 6.12. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 16, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $3.50.
On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $3.25.Jefferies initiated its Buy rating on April 04, 2024, with a $3.25 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 23 ’25 when Kim Hanjoon Alex sold 1,428 shares for $0.94 per share. The transaction valued at 1,344 led to the insider holds 930,286 shares of the business.
Mackay Sean sold 13,217 shares of LAB for $12,437 on May 23 ’25. The SVP & Chief Business Officer now owns 843,076 shares after completing the transaction at $0.94 per share. On May 23 ’25, another insider, Egholm Michael, who serves as the President & CEO of the company, sold 5,473 shares for $0.94 each. As a result, the insider received 5,150 and left with 2,741,191 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 469614560 and an Enterprise Value of 175179392. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.91 while its Price-to-Book (P/B) ratio in mrq is 1.08. Its current Enterprise Value per Revenue stands at 1.032 whereas that against EBITDA is -1.586.
Stock Price History:
The Beta on a monthly basis for LAB is 1.31, which has changed by -0.26136363 over the last 52 weeks, in comparison to a change of 0.10500872 over the same period for the S&P500. Over the past 52 weeks, LAB has reached a high of $2.41, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is 16.39%, while the 200-Day Moving Average is calculated to be -12.25%.
Shares Statistics:
LAB traded an average of 1.74M shares per day over the past three months and 2316760 shares per day over the past ten days. A total of 379.09M shares are outstanding, with a floating share count of 367.76M. Insiders hold about 3.18% of the company’s shares, while institutions hold 72.23% stake in the company. Shares short for LAB as of 1749772800 were 16159588 with a Short Ratio of 9.29, compared to 1747267200 on 17493417. Therefore, it implies a Short% of Shares Outstanding of 16159588 and a Short% of Float of 7.249999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
